The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Open accessAbstract
Drug resistance presents a challenge to the treatment of cancer patients. Many studies have focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that the tumour micro-environment confers innate resistance to therapy. Here we developed a co-culture system to systematically assay the ability of 23 stromal cell types to influence the innate resistance of 45 cancer cell lines to 35 anticancer drugs. We found that stroma-mediated resistance is common, particularly to targeted agents. We characterized further the stroma-mediated resistance of BRAF-mutant melanoma to RAF inhibitors because most patients with this type of cancer show some degree of innate resistance. Proteomic analysis showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-OH kinase (PI(3)K)–AKT signalling pathways, and immediate resistance to RAF inhibition. Immunohistochemistry experiments confirmed stromal cell expression of HGF in patients with BRAF-mutant melanoma and showed a significant correlation between HGF expression by stromal cells and innate resistance to RAF inhibitor treatment. Dual inhibition of RAF and either HGF or MET resulted in reversal of drug resistance, suggesting RAF plus HGF or MET inhibitory combination therapy as a potential therapeutic strategy for BRAF-mutant melanoma. A similar resistance mechanism was uncovered in a subset of BRAF-mutant colorectal and glioblastoma cell lines. More generally, this study indicates that the systematic dissection of interactions between tumours and their micro-environment can uncover important mechanisms underlying drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, HGF has been implicated in mediating resistance to BRAF-targeted therapies by providing an alternative BRAF-independent mechanism for ERK–MAPK activation113.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [113]
In the citing paper
“By screening cancer-fibroblast co-cultures with a panel of cytotoxic and targeted agents, Straussman et al. identified that HGF-secreting fibroblasts rescued BRAF mutant melanoma cells from the BRAF inhibitor PLX4720 [99].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [99]
In the citing paper
“The tumor microenvironment is a complex ecosystem comprised of multiple cell types that support the growth of tumor cells, facilitate tumor progression, and modulate therapeutic response to anti-cancer treatments [29,99,100,120,121].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationKalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citationSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citationUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,875
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,001
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Whittaker, S. R., Theurillat, J.-P. P., Allen, E. M. V., Wagle, N., Hsiao, J., Cowley, G. S., Schadendorf, D., Root, D. E., & Garraway, L. A. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0470 · Cited by 369
Cancer associated fibroblasts: An essential role in the tumor microenvironment
Tao, L., Huang, G., Song, H., Chen, Y., & Chen, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.6497 · Cited by 351
Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005747 · Cited by 332
Clinical Development of BRAF plus MEK Inhibitor Combinations
Subbiah, V., Baik, C. S., & Kirkwood, J. M. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.05.009 · Cited by 360
Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts
Cassidy, J. W., Caldas, C., & Bruna, A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0727 · Cited by 352
Cancer cell plasticity during tumor progression, metastasis and response to therapy
Pérez-González, A., Bévant, K., & Blanpain, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00595-y · Cited by 370
Weigelt, B., Ghajar, C. M., & Bissell, M. J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.001 · Cited by 347
Toward a Better Understanding of the Complexity of Cancer Drug Resistance
Gottesman, M. M., Lavi, O., Hall, M. D., & Gillet, J. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103111 · Cited by 337
Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunitiesPreprint
Rambow, F., Marine, J., & Goding, C. R. (2019) · Genes & Development · doi:10.1101/gad.329771.119 · Cited by 348
Elkabets, M., Pazarentzos, E., Juric, D., Sheng, Q., Pelossof, R. A., Brook, S., Benzaken, A. O., Rodon, J., Morse, N., Yan, J. J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.010 · Cited by 325
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Role of the tumor microenvironment in tumor progression and the clinical applications (Review)
YUAN, Y., JIANG, Y.-C., SUN, C.-K., & CHEN, Q.-M. (2016) · Oncology Reports · doi:10.3892/or.2016.4660 · Cited by 320
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Franklin, R. A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.659 · Cited by 317
Walsh, A. J., Cook, R. S., Sanders, M. E., Aurisicchio, L., Ciliberto, G., Arteaga, C. L., & Skala, M. C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0663 · Cited by 313
Daynes, R. A., Araneo, B. A., Ershler, W. B., Maloney, C., Li, G. Z., & Ryu, S. Y. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.12.5219 · Cited by 1,264
Majumder, B., Ulaganathan, B., Thiyagarajan, S., Radhakrishnan, P., Narasimhan, H., Dhandapani, M., Brijwani, N., Pinto, D. D., Prasath, A., Shanthappa, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms7169 · Cited by 317
Persistent Cancer Cells: The Deadly Survivors
Shen, S., Vagner, S., & Robert, C. (2020) · Cell · doi:10.1016/j.cell.2020.10.027 · Cited by 320
Challenges for assessing replicability in preclinical cancer biology
Errington, T. M., Denis, A., Perfito, N., Iorns, E., & Nosek, B. A. (2021) · eLife · doi:10.7554/elife.67995 · Cited by 345
Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 335
Alternative splicing in cancer: implications for biology and therapy
Chen, J., & Weiss, W. A. (2014) · Oncogene · doi:10.1038/onc.2013.570 · Cited by 309
The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
Xia, S., Pan, Y., Liang, Y., Xu, J., & Cai, X. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.102610 · Cited by 299
Apicella, M., Giannoni, E., Fiore, S., Ferrari, K. J., Fernández-Pérez, D., Isella, C., Granchi, C., Minutolo, F., Sottile, A., Comoglio, P. M., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.006 · Cited by 299
Kakadia, S., Yarlagadda, N., Awad, R., Kundranda, M., Niu, J., Naraev, B., Mina, L., Dragovich, T., Gimbel, M., & Mahmoud, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s182721 · Cited by 277
Molecularly targeted cancer therapy: some lessons from the past decade
Huang, M., Shen, A., Ding, J., & Geng, M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.11.004 · Cited by 296
Fibroblast activation in cancer: when seed fertilizes soil
Kužet, S.-E., & Gaggioli, C. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2467-x · Cited by 301
Jeong, S.-Y., Lee, J.-H., Shin, Y., Chung, S., & Kuh, H.-J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159013 · Cited by 287
Nanomaterials for cancer immunotherapy
Song, W., Musetti, S., & Huang, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.017 · Cited by 285
Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies
Lovly, C. M., & Shaw, A. T. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1610 · Cited by 285
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance
Ramos, P. M., & Bentires‐Alj, M. (2014) · Oncogene · doi:10.1038/onc.2014.314 · Cited by 287
Many ways to resistance: How melanoma cells evade targeted therapies
Kozar, I., Margue, C., Rothengatter, S., Haan, C., & Kreis, S. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.02.002 · Cited by 289
Polytherapy and Targeted Cancer Drug Resistance
Chatterjee, N., & Bivona, T. G. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.02.003 · Cited by 277
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3498 · Cited by 275
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T. J., Mok, S., Cass, A. A., Haynes, N. M., Kinross, K. M., Yagita∥, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 274
Self-citationRetractedA Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms
Hu, H., Piotrowska, Z., Hare, P. J., Chen, H., Mulvey, H. E., Mayfield, A., Noeen, S., Kattermann, K. E., Greenberg, M., Williams, A. F., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.003 · Cited by 269
The kinome 'at large' in cancer
Fleuren, E. D. G., Zhang, L., Wu, J., & Daly, R. J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2015.18 · Cited by 268
Targeting adaptive glioblastoma: an overview of proliferation and invasion
Xie, Q. R., Mittal, S., & Berens, M. E. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou147 · Cited by 270
Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
Niederst, M. J., & Engelman, J. A. (2013) · Science Signaling · doi:10.1126/scisignal.2004652 · Cited by 269
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
Zhang, Z., Karthaus, W. R., Lee, Y. S., Gao, V. R., Wu, C., Russo, J. W., Liu, M., Mota, J. M., Abida, W. M., Linton, E. L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.005 · Cited by 260
Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256
Resistant mechanisms to BRAF inhibitors in melanoma
Manzano, J. L., Layos, L., Bugés, C., Gil, M. D. L. L., Vilà, L., Martinez‐Balibrea, E., & Martínez‐Cardús, A. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.06.07 · Cited by 271
Stock, K., Estrada, M. F., Vidic, S., Gjerde, K., Rudisch, A., Santo, V. E., Barbier, M., Blom, S., Arundkar, S. C., Selvam, I., et al. (2016) · Scientific Reports · doi:10.1038/srep28951 · Cited by 253
Neeße, A., Frese, K. K., Bapiro, T. E., Nakagawa, T., Sternlicht, M. D., Seeley, T. W., Pilarsky, C. P., Jodrell, D. I., Spong, S. M., & Tuveson, D. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300415110 · Cited by 251
Targeting Oncogenic BRAF: Past, Present, and Future
Zaman, A., Wu, W., & Bivona, T. G. (2019) · Cancers · doi:10.3390/cancers11081197 · Cited by 252
Cancer Associated Fibroblasts: The Architects of Stroma Remodeling
Santi, A., Kugeratski, F. G., & Zanivan, S. R. (2017) · PROTEOMICS · doi:10.1002/pmic.201700167 · Cited by 251
The Role of Cancer-Associated Fibroblasts in Tumor Progression
Joshi, R. S., Kanugula, S. S., Sudhir, S., Pereira, M. P., Jain, S., & Aghi, M. K. (2021) · Cancers · doi:10.3390/cancers13061399 · Cited by 245
Weizman, N., Krelin, Y., Shabtay-Orbach, A., Amit, M., Binenbaum, Y., Wong, R. J., & Gil, Z. (2014) · Oncogene · doi:10.1038/onc.2013.357 · Cited by 281
A microfluidics platform for combinatorial drug screening on cancer biopsies
Eduati, F., Utharala, R., Madhavan, D., Neumann, U. P., Longerich, T., Cramer, T., Saez-Rodriguez, J., & Merten, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-04919-w · Cited by 239
Hepatocyte growth factor/ MET in cancer progression and biomarker discovery
Matsumoto, K., Umitsu, M., Silva, D. M. D., Roy, A., & Bottaro, D. P. (2017) · Cancer Science · doi:10.1111/cas.13156 · Cited by 238
Targeting Breast Cancer Metastasis
Jin, X., & Mu, P. (2015) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s25460 · Cited by 250
Current and future immunotherapeutic approaches in pancreatic cancer treatment
Farhangnia, P., Khorramdelazad, H., Nickho, H., & Delbandi, A. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01561-6 · Cited by 265
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 236
Microfluidic modelling of the tumor microenvironment for anti-cancer drug development
Shang, M., Soon, R. H., Lim, C. T., Khoo, B. L., & Han, J. (2019) · Lab on a Chip · doi:10.1039/c8lc00970h · Cited by 227
Targeting tumour-supportive cellular machineries in anticancer drug development
Dobbelstein, M., & Moll, U. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4201 · Cited by 233
Dienstmann, R., Villacampa, G. J., Sveen, A., Mason, M. J., Niedzwiecki, D., Nesbakken, A., Moreno, V. R., Warren, R. S., Lothe, R. A., & Guinney, J. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz287 · Cited by 229
In vitro models of medulloblastoma: Choosing the right tool for the job
Ivanov, D. P., Coyle, B., Walker, D. A., & Grabowska, A. M. (2016) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2016.07.028 · Cited by 231
Smith, M. P., Sánchez‐Laorden, B. L., O’Brien, K., Brunton, H., Ferguson, J., Young, H. L., Dhomen, N. S., Flaherty, K. T., Frederick, D. T., Cooper, Z. A., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-1007 · Cited by 235
Self-citationHGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
Fu, J., Su, X., Li, Z., Deng, L., Liu, X., Feng, X., & Peng, J. (2021) · Oncogene · doi:10.1038/s41388-021-01863-w · Cited by 235
Wang, P., Ji, Y., Zhang, X., Zhao, L., Yan, Z.-Z., Zhang, P., Shen, L., Yang, X., Fang, J., Tian, S., et al. (2017) · Nature Medicine · doi:10.1038/nm.4290 · Cited by 221
Linking the future of anticancer metal-complexes to the therapy of tumour metastases
Bergamo, A., & Sava, G. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00134j · Cited by 225
Pathways and therapeutic targets in melanoma
Shtivelman, E., Davies, M. A., Hwu, P., Yang, J. C.-H., Lotem, M., Oren, M., Flaherty, K. T., & Fisher, D. E. (2014) · Oncotarget · doi:10.18632/oncotarget.1892 · Cited by 226
Self-citationResistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh, S. J., Rizos, H., Scolyer, R. A., & Long, G. V. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.04.005 · Cited by 224
Evaluation of Drug Combination Effect Using a Bliss Independence Dose–Response Surface Model
Liu, Q., Yin, X., Languino, L. R., & Altieri, D. C. (2018) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2018.1437071 · Cited by 208
Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors
Miao, L., Liu, Q., Lin, C. M., Luo, C., Wang, Y., Liu, L., Yin, W., Hu, S., Kim, W. Y., & Huang, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0866 · Cited by 215
Carcinoma‐associated fibroblasts: Non‐neoplastic tumour‐promoting mesenchymal cells
Polanska, U. M., & Orimo, A. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24347 · Cited by 208
Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts
Avery, D., Govindaraju, P., Jacob, M., Todd, L., Monslow, J., & Puré, E. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.003 · Cited by 206
Ashcraft, K. A., Peace, R. M., Betof, A. S., Dewhirst, M. W., & Jones, L. W. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0887 · Cited by 217
Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
Cui, J. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401427c · Cited by 216
Johnson, D. B., Flaherty, K. T., Weber, J. S., Infante, J. R., Kim, K. B., Kefford, R. F., Hamid, O., Schuchter, L. M., Cebon, J. S., Sharfman, W. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3535 · Cited by 219
Self-citationGirotti, M. R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies, L., Whittaker, S., Saturno, G., Viros, A., Pedersen, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.006 · Cited by 212
Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches
Saraon, P., Pathmanathan, S., Snider, J. D., Lyakisheva, A., Wong, V., & Štagljar, I. (2021) · Oncogene · doi:10.1038/s41388-021-01841-2 · Cited by 215
Mikubo, M., Inoue, Y., Liu, G., & Tsao, M. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.017 · Cited by 218
Fletcher-Sananikone, E., Kanji, S., Tomimatsu, N., Di Cristofaro, L. F. M., Kollipara, R. K., Saha, D., Floyd, J. R., Sung, P., Hromas, R., Burns, T. C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0752 · Cited by 212
Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
Song, Y., Bi, Z., Liu, Y., Qin, F., Wei, Y., & Wei, X. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.05.006 · Cited by 212
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Wu, P., Gao, W. Q., Su, M., Nice, E. C., Zhang, W., Lin, J., & Xie, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641469 · Cited by 218
Drug resistance to targeted therapies: Déjà vu all over again
Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 222
Fibroblasts and myofibroblasts of the intestinal lamina propria in physiology and disease
Roulis, M., & Flavell, R. A. (2016) · Differentiation · doi:10.1016/j.diff.2016.05.002 · Cited by 211
Martinez‐Outschoorn, U., Sotgia, F., & Lisanti, M. P. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.03.002 · Cited by 211
The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
Maroun, C. R., & Rowlands, T. M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.014 · Cited by 206
Lochhead, P., Chan, A. T., Nishihara, R., Fuchs, C. S., Beck, A. H., Giovannucci, E., & Ogino, S. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.81 · Cited by 206
Self-citationChen, G., Chakravarti, N., Aardalen, K., Lazar, A. J., Tetzlaff, M. T., Wubbenhorst, B. S., Kim, S.-B., Kopetz, S., Ledoux, A. A., Gopal, Y. N. V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3003 · Cited by 205
CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion
Günaydın, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668349 · Cited by 211
Heßmann, E., Patzak, M. S., Klein, L., Chen, N., Kari, V., Ramu, I., Bapiro, T. E., Frese, K. K., Gopinathan, A., Richards, F. M., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-311954 · Cited by 205
Luebker, S. A., & Koepsell, S. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00268 · Cited by 194
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Mesenchymal Cells in Colon Cancer
Koliaraki, V., Pallangyo, C. K., Greten, F. R., & Kollias, G. A. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.049 · Cited by 200
Targeted Therapy in Melanoma and Mechanisms of Resistance
Czarnecka, A. M., Bartnik, E., Fiedorowicz, M., & Rutkowski, P. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134576 · Cited by 213
Phillips, G. D. L., Fields, C. T., Li, G., Dowbenko, D. J., Schaefer, G., Miller, K. D., André, F., Burris, H. A., Albain, K. S., Harbeck, N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0358 · Cited by 198
Cytokines in cancer drug resistance: Cues to new therapeutic strategies
Jones, V. S., Huang, R.-Y., Chen, L.-P., Chen, Z., Fu, L., & Huang, R.-P. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.03.005 · Cited by 199
Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting
Rimal, R., Desai, P. B., Daware, R., Hosseinnejad, A., Prakash, J., Lammers, T., & Singh, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114504 · Cited by 210
Nathanson, K. L., Martin, A., Wubbenhorst, B. S., Greshock, J. D., Letrero, R., D'Andrea, K. P., O'Day, S. J., Infante, J. R., Falchook, G. S., Arkenau, H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0827 · Cited by 200
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care
Kodack, D. P., Farago, A. F., Dastur, A., Held, M. A., Dardaei, L., Friboulet, L., von Flotow, F., Damon, L. J., Lee, D., Parks, M. K., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.051 · Cited by 196
Systematic identification of signaling pathways with potential to confer anticancer drug resistance
Martz, C. A., Ottina, K. A., Singleton, K. R., Jasper, J. S., Wardell, S. E., Peraza-Penton, A., Anderson, G. R., Winter, P. S., Wang, T., Alley, H. M., et al. (2014) · Science Signaling · doi:10.1126/scisignal.aaa1877 · Cited by 189
Self-citationTumor Abnormality-Oriented Nanomedicine Design
Zhou, Q., Xiang, J., Qiu, N., Wang, Y., Piao, Y., Shao, S., Tang, J., Zhou, Z., & Shen, Y. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00062 · Cited by 203
Microfluidic 3D models of cancer
Sung, K. E., & Beebe, D. J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.07.002 · Cited by 190
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors
Jonas, O., Landry, H. M., Fuller, J. E., Santini, J. T., Baselga, J., Tepper, R. I., Cima, M. J., & Langer, R. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010564 · Cited by 189
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189
Hall, A., Meyle, K. D., Lange, M. K., Klima, M., Sanderhoff, M., Dahl, C., Abildgaard, C., Thorup, K., Moghimi, S. M., Jensen, P. B., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.965 · Cited by 191
Personalized Nanomedicine: A Revolution at the Nanoscale
Fornaguera, C., & García, M. J. N. (2017) · Journal of Personalized Medicine · doi:10.3390/jpm7040012 · Cited by 189
The Pancreatic Cancer Microenvironment
Dougan, S. K. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000288 · Cited by 193
Metadata
- Authors
- Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., Cooper, Z. A., Chapman, P. B., Solit, D. B., Ribas, A., Lo, R. S., Flaherty, K. T., Ogino, S., Wargo, J. A., & Golub, T. R.
- Affiliations
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Massachusetts General Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of California, Los Angeles (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Golub, Todd R.
- ORCID
- Venue
- Nature
- Published
- 2012-07
- Volume
- 487
- Issue
- 7408
- Pages
- 500-504
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3711467
- OpenAlex
- W2055624262
- Semantic Scholar
- d51bc0a1730710ad5e74705bff1a2f756c61fc28
- Cited by
- 1,771
- References
- 30
- Citations by year
- 2026: 51 · 2025: 48 · 2024: 68 · 2023: 93 · 2022: 98 · 2021: 102 · 2020: 114 · 2019: 115 · 2018: 138 · 2017: 150 · 2016: 154 · 2015: 172 · 2014: 215 · 2013: 196 · 2012: 53
- FWCI
- 82.21
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA166480, U54CA112962, P50CA093683, UM1CA186709)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- RAF inhibitors, vemurafenib, drug resistance, tumor microenvironment, stromal cells, hepatocyte growth factor, MAPK signaling, PI3K/Akt signaling, combination therapy, co-culture model, targeted therapy, non-specific immunity, cancer cell lines, proteomics, immunohistochemistry, immunofluorescence
- MeSH terms
- Vemurafenib, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Indoles, Melanoma, Mutation, Prognosis, Sulfonamides, Signal Transduction, Stromal Cells, Hepatocyte Growth Factor, Coculture Techniques, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Phosphatidylinositol 3-Kinases, Proteomics, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
